These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 15477320)

  • 21. Phenotypic analysis of familial breast cancer: comparison of BRCAx tumors with BRCA1-, BRCA2-carriers and non-familial breast cancer.
    Aloraifi F; Alshehhi M; McDevitt T; Cody N; Meany M; O'Doherty A; Quinn CM; Green AJ; Bracken A; Geraghty JG
    Eur J Surg Oncol; 2015 May; 41(5):641-6. PubMed ID: 25736863
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Contralateral risk-reducing mastectomy in young women.
    Merck B
    Breast Cancer Res Treat; 2010 Sep; 123 Suppl 1():29-32. PubMed ID: 20711671
    [No Abstract]   [Full Text] [Related]  

  • 23. Current perspectives on BRCA1- and BRCA2-associated breast cancers.
    Phillips KA
    Intern Med J; 2001 Aug; 31(6):349-56. PubMed ID: 11529589
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Environment and genetics: Making sense of the noise.
    Petherick A
    Nature; 2012 May; 485(7400):S64-5. PubMed ID: 22648504
    [No Abstract]   [Full Text] [Related]  

  • 25. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.
    Walsh T; Casadei S; Coats KH; Swisher E; Stray SM; Higgins J; Roach KC; Mandell J; Lee MK; Ciernikova S; Foretova L; Soucek P; King MC
    JAMA; 2006 Mar; 295(12):1379-88. PubMed ID: 16551709
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families.
    Antoniou AC; Durocher F; Smith P; Simard J; Easton DF;
    Breast Cancer Res; 2006; 8(1):R3. PubMed ID: 16417652
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Breast cancer risk assessment and genetic testing: complexities, conundrums, and community.
    Peshkin BN
    Breast Dis; 2006-2007; 27():1-3. PubMed ID: 17917137
    [No Abstract]   [Full Text] [Related]  

  • 28. The case for individualized screening recommendations for breast cancer.
    Bradbury A; Olopade OI
    J Clin Oncol; 2006 Jul; 24(21):3328-30. PubMed ID: 16801629
    [No Abstract]   [Full Text] [Related]  

  • 29. BRCA1 and BRCA2 mutation frequency in women evaluated in a breast cancer risk evaluation clinic.
    Shih HA; Couch FJ; Nathanson KL; Blackwood MA; Rebbeck TR; Armstrong KA; Calzone K; Stopfer J; Seal S; Stratton MR; Weber BL
    J Clin Oncol; 2002 Feb; 20(4):994-9. PubMed ID: 11844822
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility.
    de Jong MM; Nolte IM; te Meerman GJ; van der Graaf WT; Oosterwijk JC; Kleibeuker JH; Schaapveld M; de Vries EG
    J Med Genet; 2002 Apr; 39(4):225-42. PubMed ID: 11950848
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oral contraceptives, salpingo-oophorectomy and hormone replacement therapy in BRCA1-2 mutation carriers.
    Biglia N; Mariani L; Ponzone R; Sismondi P
    Maturitas; 2008 Jun; 60(2):71-7. PubMed ID: 18472232
    [No Abstract]   [Full Text] [Related]  

  • 32. [Are the hereditary forms of BRCA1 and BRCA2 breast cancer sensitive to estrogens?].
    Pujol P; This P; Noruzinia M; Stoppa-Lyonnet D; Maudelonde T
    Bull Cancer; 2004; 91(7-8):583-91. PubMed ID: 15381448
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of systemic hormone therapy in BRCA mutation carriers.
    Domchek S; Kaunitz AM
    Menopause; 2016 Sep; 23(9):1026-7. PubMed ID: 27504919
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population.
    Meindl A;
    Int J Cancer; 2002 Feb; 97(4):472-80. PubMed ID: 11802209
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Mammography screening--neglected aspects of radiation risks].
    Kuni H; Schmitz-Feuerhake I; Dieckmann H
    Gesundheitswesen; 2003 Jul; 65(7):443-6. PubMed ID: 12891476
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
    Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
    Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes.
    Berry DA; Iversen ES; Gudbjartsson DF; Hiller EH; Garber JE; Peshkin BN; Lerman C; Watson P; Lynch HT; Hilsenbeck SG; Rubinstein WS; Hughes KS; Parmigiani G
    J Clin Oncol; 2002 Jun; 20(11):2701-12. PubMed ID: 12039933
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gynecological-endocrinological aspects in women carriers of BRCA1/2 gene mutations.
    Doren A; Vecchiola A; Aguirre B; Villaseca P
    Climacteric; 2018 Dec; 21(6):529-535. PubMed ID: 30295091
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Can a computer-based system be used to educate women on genetic testing for breast cancer susceptibility?
    Schwartz MD; Tercyak KP; Peshkin BN; Valdimarsdottir H
    Nat Clin Pract Oncol; 2005 Jan; 2(1):24-5. PubMed ID: 16264852
    [No Abstract]   [Full Text] [Related]  

  • 40. The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers.
    Metcalfe KA; Lynch HT; Ghadirian P; Tung N; Olivotto IA; Foulkes WD; Warner E; Olopade O; Eisen A; Weber B; McLennan J; Sun P; Narod SA
    Gynecol Oncol; 2005 Jan; 96(1):222-6. PubMed ID: 15589605
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.